Evidence map›Paper›PMID 21499303›Full record

ArticleOncogene2011

Wwox inactivation enhances mammary tumorigenesis.

S K Abdeen, Z Salah, B Maly, Y Smith, R Tufail, M Abu-Odeh, N Zanesi, C M Croce, Z Nawaz, R I Aqeilan

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 57 citations in OpenAlex.

  1. WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Article
  4. WWOX and metabolic regulation in normal and pathological conditions.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Pleiotropic tumor suppressor functions of WWOX antagonize metastasis.Signal transduction and targeted therapy · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Modeling WWOX Loss of FunctionFrontiers in oncology · 2018
    Review
  15. Review
  16. Review
  17. Frontiers in oncology · 2018
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

S K AbdeenThe Lautenberg Center for General and Tumor Immunology, Department of Immunology and Cancer Research-IMRIC, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Z Salah
B Maly
Y Smith
R Tufail
M Abu-Odeh
N Zanesi
C M Croce
Z Nawaz
R I Aqeilan
Hebrew University of Jerusalem · ILThe Ohio State University · USUniversity of Miami · US

Funding

Roles of Novel Protein Complexes in Estrogen and Progesterone Receptor SignalingR01DK079217 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI NAWAZ, ZAFAR · 2009 to 2012
$1.5M
Role of E6-AP in the Development of Prostate CancerR01DK060907 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI NAWAZ, ZAFAR · 2001 to 2004
$876k
NIDDK NIH HHS R01DK060907NIDDK NIH HHS R01 DK079217
6 · The paper itself

Abstract

Breast cancer is the leading cause of cancer-related death in women worldwide. Expression of the WWOX tumor suppressor is absent or reduced in a large proportion of breast tumors suggesting that loss of WWOX may contribute to breast tumorigenesis. Wwox-deficient mice die by 3-4 weeks of age precluding adult tumor analysis. To evaluate the effect of WWOX-altered expression on mammary tumor formation, the Wwox-heterozygous allele was back crossed onto the C3H mammary tumor-susceptible genetic background (Wwox(C3H)+/-) and incidence of mammary tumor formation was evaluated. Although 50% of the female Wwox(C3H)+/- mice developed mammary carcinomas, only 7% of Wwox(C3H)+/+ mice did. Intriguingly, mammary tumors in Wwox(C3H)+/- mice frequently lost WWOX protein expression suggesting a genetic predisposition toward mammary tumorigenesis. Immunohistochemical staining of hormone receptors revealed loss of estrogen receptor-α (ER) and progesterone receptor in the majority of these tumors. In vitro, depletion of WWOX in MCF7 ER-positive cells led to reduced ER expression and reduced sensitivity to tamoxifen and estrogen treatment and was associated with enhanced survival and anchorage-independent growth. Finally, cDNA array analyses of murine normal mammary epithelial cells and mammary tumors identified 163 significantly downreguated and 129 upregulated genes in the tumors. The majority of differentially expressed genes were part of pathways involved in cellular movement, cell-to-cell signaling and interaction, cellular development, cellular growth and proliferation and cell death. These changes in gene expression of mouse mammary tumors in Wwox(C3H)+/- mice resemble, at least in part, human breast cancer development. Our findings demonstrate the critical role that the WWOX tumor suppressor gene has in preventing tumorigenesis in breast cancer.

Indexed as

AllelesAnimalsBiomarkers, TumorCell DeathCell Line, TumorCrosses, GeneticFemaleHumansImmunohistochemistryMammary Neoplasms, AnimalMiceMice, Inbred C3HMice, TransgenicOxidoreductasesReceptors, EstrogenSignal TransductionBiomarkers, TumorOxidoreductasesReceptors, EstrogenWW Domain-Containing OxidoreductaseWwox protein, mouse

Identifiers

PMID21499303
OpenAlexW2091199878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.